ArticlePloS one2025
Optimizing lipocalin sequence classification with ensemble deep learning models.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence in drug discovery from advanced molecular representation to pipeline applications.Frontiers in bioinformatics · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep learning (DL) has become a powerful tool for the recognition and classification of biological sequences. However, conventional single-architecture models often struggle with suboptimal predictive performance and high computational costs. To address these challenges, we present EnsembleDL-Lipo, an innovative ensemble deep learning framework that combines Convolutional Neural Networks (CNNs) and Deep Neural Networks (DNNs) to enhance the identification of lipocalin sequences. Lipocalins are multifunctional extracellular proteins involved in various diseases and stress responses, and their low sequence similarity and occurrence in the 'twilight zone' of sequence alignment present significant hurdles for accurate classification. These challenges necessitate efficient computational methods to complement traditional, labor-intensive experimental approaches. EnsembleDL-Lipo overcomes these issues by leveraging a set of PSSM-based features to train a large ensemble of deep learning models. The framework integrates multiple feature representations derived from position-specific scoring matrices (PSSMs), optimizing classification performance across diverse sequence patterns. The model achieved superior results on the training dataset, with an accuracy (ACC) of 97.65%, recall of 97.10%, Matthews correlation coefficient (MCC) of 0.95, and area under the curve (AUC) of 0.99. Validation on an independent test set further confirmed the robustness of the model, yielding an ACC of 95.79%, recall of 90.48%, MCC of 0.92, and AUC of 0.97. These results demonstrate that EnsembleDL-Lipo is a highly effective and computationally efficient tool for lipocalin sequence identification, significantly outperforming existing methods and offering strong potential for applications in biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.